Le Lézard
Classified in: Health, Science and technology

WuXi Biologics and Harbour BioMed Announce Strategic Development and Manufacturing Partnership


WuXi Biologics' first collaborative project based on novel fully human antibody platform - HCAb ("heavy chain only" antibodies)

SHANGHAI and CAMBRIDGE, Mass., June 24, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Harbour BioMed, a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and immunological diseases, today announced an initial strategic collaboration for the development and manufacturing of Harbour's leading HCAb antibody. The collaboration with WuXi Biologics will support the supply of Harbour's products for clinical trials under Investigational New Drug (IND) applications in China and worldwide.

"In about a year's time, our scientists have moved our leading HCAb molecule into IND enabling stage. We are excited to collaborate with WuXi Biologics to accelerate further development of this molecule. This collaboration is aligned with our strategy to partner with industry leaders to bring forward innovative therapeutics that will help patients," said Dr. Jingsong Wang, CEO of Harbour BioMed.

"Harbour's trust in WuXi Biologics to develop this novel format of HCAb is a strong testament of WuXi Biologics as a global leader in technology," commented Dr. Chris Chen, CEO of WuXi Biologics, "We have enabled more than 20 complex molecules to the clinic including different bispecific formats, ADCs, fusion proteins and novel protein scaffolds. We aim to empower anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing."

About Harbour BioMed

Harbour BioMed is a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases. The company's discovery and development programs are built around its two patented transgenic mouse platforms (Harbour Mice) for human antibody therapeutic discovery. The company is building its proprietary pipeline through its innovative internal discovery programs, and through in-licensing clinical stage assets that strategically fit its internal portfolio. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. For additional information, please visit http://www.harbourbiomed.com.

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

SOURCE WuXi Biologics


These press releases may also interest you

at 16:35
reAlpha Tech Corp. Announces Financial Results for the Quarter Ended March 31, 2024
reAlpha Tech Corp. ("reAlpha," the "Company," "us," "we" or "our") , a real estate technology company focused on developing, utilizing and commercializing real estate-focused artificial intelligence ("AI") technologies, today reports financial...

at 16:35
Stem Announces Appointment of AI Industry Leader as New Independent Director
Stem, Inc. , a global leader in artificial intelligence (AI)-driven clean energy software and services, today announced the appointment of Gerard Cunningham to the Company's Board of Directors (the "Board"), effective April 19, 2024. Mr. Cunningham...

at 16:30
Intelligent Living Application Group Inc. Granted Extension to Meet Nasdaq Minimum Bid Price Requirement
Intelligent Living Application Group Inc. ("Intelligent Living" or the "Company"), a premium lockset manufacturer in Hong Kong, announced today that, on April 17, 2024, the Company received a written notification from the NASDAQ Stock Market Listing...

at 16:27
FDA Roundup: April 19, 2024
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:15
Universal Logistics Holdings, Inc. Named a 2023 Supplier of the Year by General Motors
Universal Logistics Holdings, Inc. was named a 2023 Supplier of the Year by General Motors ("GM"). GM celebrated honorees at its 32nd annual Supplier of the Year event in Miami, Florida last week....

at 16:10
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

More news about Science and technology...


News published on and distributed by: